Movie Trailers Illustrating My NAD Deficiencies


Tell a friend:


An intronic point mutation was identified in the E1alpha PDH gene from a boy with delayed development and lactic acidosis, an X-linked disorder associated with a partial defect in pyruvate dehydrogenase (PDH) activity. Protein analysis demonstrated a corresponding decrease in immunoreactivity of the alpha and beta subunits of the PDH complex.

In addition to the normal spliced mRNA product of the E1alpha PDH gene, patient samples contained significant levels of an aberrantly spliced mRNA with the first 45 nucleotides of intron 7 inserted in-frame between exons 7 and 8. The genomic DNA analysis found no mutation in the coding regions but revealed a hemizygous intronic G to A substitution 26 nucleotides downstream from the normal exon 7 5'-splice site. Splicing experiments in COS-7 cells demonstrated that this point mutation at intron 7 position 26 is responsible for the aberrant splicing phenotype, which involves a switch from the use of the normal 5'-splice site (intron 7 position 1) to the cryptic 5'-splice site downstream of the mutation (intron 7 position 45).

The intronic mutation is unusual in that it generates a consensus binding motif for the splicing factor, SC35, which normally binds to exonic enhancer elements resulting in increased exon inclusion. Thus, the aberrant splicing phenotype is most likely explained by the generation of a de novo splicing enhancer motif, which activates the downstream cryptic 5'-splice site. The mutation documented here is a novel case of intron retention responsible for a human genetic disease.

About the Authors

Miné M, Brivet M, Touati G, Grabowski P, Abitbol M, Marsac C. (2003) Splicing error in E1alpha pyruvate dehydrogenase mRNA caused by novel intronic mutation responsible for lactic acidosis and mental retardation. J Biol Chem. 2003 Apr 4;278(14):11768-72. Laboratoire Centre de Recherche Thérapeutique en Ophtalmologie, Faculté de Médecine Necker, 156 rue de Vaugirard 75015 Paris, France.

Comments


Dr_Abram_Hoffer

  • Posted on 05/16/2010 07:30 pm
This new work with NAD Therapy is very exciting and I think is right on target. It is indeed an energy-metabolic-deficiency (EMD) because in the absence of this coenzyme cycle almost all the reactions in the body run down... I congratulate Theo Verwey and his colleagues for this remarkable advance in using this concept and in using a simple test, the ratio of pyruvate to lactate as a diagnostic measure, to indicate the dose, duration of treatment etc.

<

|